Bioversys reported first clinical proof‑of‑concept data for alpibectir (BVL‑GSK098) combined with ethionamide in pulmonary tuberculosis, publishing phase IIa early bactericidal activity results in the New England Journal of Medicine. The combination showed activity that suggests potential to overcome existing resistance mechanisms. The data provide early clinical validation of alpibectir’s mode of action and its ability to potentiate ethionamide, a legacy antitubercular agent, offering a strategy to repurpose older drugs against resistant Mycobacterium tuberculosis strains. Given the global burden of drug‑resistant TB, the finding marks a notable milestone for antibiotic innovation, though larger trials are needed to confirm clinical efficacy, safety and real‑world applicability. Next steps: plan and initiate larger randomized trials, define optimal dosing and safety profile, and engage global public‑health partners for development in high‑burden settings.